Advancing Alzheimer’s biomarker detection: SPEAR UltraDetect™ pTau 217 surpasses leading technologies

This study evaluates the performance of the SPEAR UltraDetect™ pTau 217 immunoassay in detecting in blood samples from Alzheimer’s disease (AD) patients. It aimed to assess its accuracy and specificity in distinguishing AD from control groups and compare its performance with a well-established commercial assay, demonstrating the potential of SPEAR UltraDetect™ pTau 217 as an ultra-sensitive tool for early AD detection, clinical trial patient selection, and disease progression monitoring.